西咪替丁治疗上消化道出血的对照试验。
Controlled trial of cimetidine in upper gastrointestinal haemorrhage.
作者信息
La Brooy S J, Misiewicz J J, Edwards J, Smith P M, Haggie S J, Libman L, Sarner M, Wyllie J H, Croker J, Cotton P
出版信息
Gut. 1979 Oct;20(10):892-5. doi: 10.1136/gut.20.10.892.
One hundred and one patients were studied in a double-blind controlled trial to assess the role of oral cimetidine in preventing the continuation or recurrence of acute upper gastrointestinal haemorrhage from various sources, chiefly peptic ulcer. The dose of cimetidine was 800 mg on entering the study followed by 400 mg six hourly. The source of bleeding was identified endoscopically in 96% of patients, peptic ulcer comprising 70%. Bleeding continued or recurred in 11 of 51 (21.5%) of patients on cimetidine and in 12 of 50 (24%) of patients on placebo. Analysis of the effect of cimetidine according to age or severity of bleeding showed no significant advantage for the drug.
在一项双盲对照试验中，对101名患者进行了研究，以评估口服西咪替丁在预防各种原因（主要是消化性溃疡）引起的急性上消化道出血持续或复发中的作用。进入研究时西咪替丁的剂量为800毫克，随后每6小时服用400毫克。96%的患者通过内镜确定了出血来源，其中消化性溃疡占70%。接受西咪替丁治疗的51名患者中有11名（21.5%）出血持续或复发，接受安慰剂治疗的50名患者中有12名（24%）出血持续或复发。根据年龄或出血严重程度对西咪替丁的效果进行分析，结果显示该药物没有显著优势。
Zotero 插件